Global Biotech Execs to Converge on San Francisco January 7–9 for 5th Annual Biotech Showcase™

Global Biotech Execs to Converge on San Francisco January 7–9 for 5th Annual Biotech Showcase™

2013 investor and partnering conference, to be held January 7–9, 2013 in San Francisco, CA at Parc 55 Wyndham San Francisco - Union Square, is an innovation showcase for life science investors. The event attracts executives from emerging private and public biotechnology and life science companies interested in presenting to raise their profile with potential investors and collaborators.

Biotech Showcase is co-produced annually by Demy-Colton Life Science Advisors and EBD Group. Both organizations have a long history of providing high-quality business support programs and services to the biotechnology industry.

Participants include private and public equity investors, industry analysts, bankers, pharmaceutical and biotechnology industry executives as well as other industry professionals. The 2013 edition will feature nearly 250+ corporate presentations as well as a robust program that will address the current environment for investment and growth, best practices, important therapeutic areas and business development.

, Principal of , said: “In a few short years, this conference has become a ‘must attend’ investor conference for the biotech industry’s emerging innovator companies. It’s where investors hear updates from management teams and learn about new investment opportunities. According to past attendees, Biotech Showcase is where the action is. Investors and business development executives can hear from and meet with management teams informally as well as formally facilitated by the world’s leading partnering system developed by EBD Group.”

“Biotech Showcase is where money meets life science innovation,” said , President of EBD Group. “The event offers a wide spectrum of investing and partnering opportunities with companies ranging from innovative biotechnology, to specialty pharma, platform, tool and molecular diagnostic companies. This is where private and public investors collaborate.”

The 2012 event featured corporate presentations by more than 240 public and private biotechnology and life science companies, and attracted more than 1,300 registrants who engaged in more than 2,000 one-to-one meetings.

Biotech Showcase is powered by , the industry’s most advanced partnering system, that enables delegates to efficiently identify and arrange meetings with potential investors and partners.

Companies interested in requesting a presentation slot can do so online at .

before November 30 and save USD 200.

Biotech Showcase™ is an investor and partnering conference devoted to providing private and small- and mid-cap biotechnology companies an opportunity to present to and meet with investors and biopharmaceutical executives during the course of one of the largest annual healthcare conferences that attracts investors and biopharmaceutical executives from around the world.

The 2012 event showed a substantial increase in the number of presenting companies, as well as significant growth in the number of attendees and one-to-one meetings. Now in its fifth year, Biotech Showcase 2013 is expected to feature presentations by close to 250 public and private companies and attract more than 1,500 attendees. The event will host a full program of topical plenary sessions and workshops.

Follow Biotech Showcase 2013 on Twitter: (hashtag: #BTS13).

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:

EBD Group’s sophisticated web-based partnering service, , is also used as the partnering engine at numerous third-party events around the world, and is the open online community of life science dealmakers that enhances partnering experiences all year long. Outside of the conference format, EBD Group’s consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies.

EBD Group has offices in the USA and Europe.

For more information please visit .

Demy-Colton Life Science Advisors is focused exclusively on facilitating the growth of the life science industry. Demy-Colton has developed a number of high-value added conferences to address the business and development needs of the biotechnology industry; it provides partnering services and it has helped launch a unique investor website and newsletter.

Demy-Colton's conferences include:

Demy-Colton's online partnering systems, and , support Demy-Colton's events and facilitates investor and venture meetings for the pharma industry and partnering for other organizations.

Demy-Colton Life Science Advisors has also been involved in the launch and development of The Life Sciences Report, a unique investor newsletter where third-party experts share their opinions on investment opportunities. To subscribe to this free newsletter, click . To become a sponsor, please contact Sara Jane Demy at .

For more information please visit .

Photos/Multimedia Gallery Available:

Suggested Articles

In this week's EuroBiotech Report, GSK, Immatics strike cell therapy deal, Vifor buys priority review voucher and PharmaMar gets PDUFA date.

In our EuroBiotech roundup this week, U.K. creates life science zones, Genmab to ramp up R&D spending and Pfizer backs cancer biotech. 

Spruce Biosciences raised $88 million from the likes of Abingworth and Omega Funds to take the drug to the next level: a late-stage study in adults.